QuidelOrtho Corporation (QDEL) carries a Roarable Rating of E (Strong Sell) with 21/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, QuidelOrtho Corporation (NASDAQ: QDEL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $14.03 (+5.89% 1D, market cap $908.6M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 6/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, QDEL ranks #965 in composite RQD confidence.
Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), QDEL carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACHV (Achieve Life Sciences Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $702.8M) and MYGN (Myriad Genetics Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $607.4M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).
Per QDEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-28, CIK 0001906324), QuidelOrtho Corporation generated $2.73B in revenue (-1.9% YoY), -$1.13B in net income, and -$83.0M in free cash flow against $5.77B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While QDEL currently carries a cautious 21/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.71) and Max Pain ($14.73) forces dealer call-delta covering toward $37.36.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
QuidelOrtho Corporation (QDEL) surged +5.89% to $14.03, trading at 16% of its 52-week range ($9.92 – $35.58). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance Australia report covering QuidelOrtho Corporation (QDEL) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering QuidelOrtho Corporation (QDEL) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering QuidelOrtho Corporation (QDEL) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering QuidelOrtho Corporation (QDEL) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering QuidelOrtho Corporation (QDEL) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering QuidelOrtho Corporation (QDEL) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering QuidelOrtho Corporation (QDEL) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering QuidelOrtho Corporation (QDEL) market action, institutional positioning, and fundamental catalysts.
QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 62 of its Science Bytes podcast, exploring best practices in AI and informatics to make lab operations smoot
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -1.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on QDEL today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for QDEL. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, QuidelOrtho Corporation (QDEL) ranks #965 by composite RQD confidence (21/100, grade E) and #370 by equity capitalization ($908.6M). Within this direct 5-issuer industry benchmark cohort, NNNN leads on earnings valuation at 83.6x trailing P/E, while NNNN leads on capital efficiency and profitability with 17.0% ROIC and 87.2% gross margin. MYGN currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with QDEL at 21/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| QDEL
ACTIVE
QuidelOrtho Corporation | E | 21/100 | — | — | -35.0% | +5.89% | $908.6M | Benchmark Subject |
| ACHV Achieve Life Sciences Inc. | D- | 39/100 | — | — | -35.0% | -3.22% | $702.8M | /achv-vs-qdel → |
| MYGN Myriad Genetics Inc. | D | 47/100 | — | 69.9% | -35.0% | -7.87% | $607.4M | /mygn-vs-qdel → |
| NNNN Anbio Biotechnology (Class A) | D- | 35/100 | 83.6x | 87.2% | 17.0% | +4.46% | $483.5M | /nnnn-vs-qdel → |
| NTLA Intellia Therapeutics Inc. | E | 25/100 | — | — | -35.0% | -6.50% | $1.75B | /ntla-vs-qdel → |
In its most recent audited fiscal period (FY2025, filed 2025-12-28), QuidelOrtho Corporation (QDEL) reported GAAP revenue of $2.73B (-1.9% vs. FY2024 revenue of $2.78B , and -8.9% cumulative change since FY2023) , GAAP net income of -$1.13B, operating cash flow of $105.2M, and free cash flow of -$83.0M (+26.0% YoY). On the balance sheet, QDEL closed FY2025 with $5.77B in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-28 | $2.73B | -$1.13B | $105.2M | -$83.0M | $5.77B | — |
| FY2024 (FY) | 2024-12-29 | $2.78B | -$2.05B | $83.0M | -$112.1M | $6.42B | — |
| FY2023 (FY) | 2023-12-31 | $3.00B | -$10.1M | $280.2M | $280.2M | — | — |
As of 2026-11-03, QuidelOrtho Corporation (NASDAQ: QDEL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $14.03 (+5.89% 1D, market cap $908.6M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 6/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, QDEL ranks #965 in composite RQD confidence.
Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), QDEL carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACHV (Achieve Life Sciences Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $702.8M) and MYGN (Myriad Genetics Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $607.4M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).
Per QDEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-28, CIK 0001906324), QuidelOrtho Corporation generated $2.73B in revenue (-1.9% YoY), -$1.13B in net income, and -$83.0M in free cash flow against $5.77B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
QDEL last traded at $14.03 (+5.89% on volume of 2,857,712 shares), positioning the stock +10.39% above its 50-day simple moving average ($12.71) and -12.59% below its 200-day simple moving average ($16.05). Across its 52-week range of $9.92 to $35.58, QDEL sits at the 16.0% percentile with a 14-day RSI of 50.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($12.28 to $15.78).
QuidelOrtho Corporation (QDEL) earns a live Roarable RQD composite score of 21/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $14.03 (+5.89% 1D, market capitalization $908.6M).
QuidelOrtho Corporation (QDEL) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry. The profile identifies the company as a diagnostics participant with a market capitalization of $0.9B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-28), QuidelOrtho Corporation (QDEL) reported $2.73B in annual revenue (up from $2.78B in FY2024, -1.9% YoY) and -$1.13B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($3.00B revenue, -$10.1M net income) through FY2025, QDEL scaled operating cash flow to $105.2M and free cash flow to -$83.0M, backed by $5.77B in total assets against $0 in total debt.
Upstream dependencies, downstream customers, and sector correlations beyond the Health Care sector classification are not identified in the source data.
Real-time company headlines, analyst actions, and sector developments for QuidelOrtho Corporation (QDEL) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance Australia report covering QuidelOrtho Corporation (QDEL) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering QuidelOrtho Corporation (QDEL) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering QuidelOrtho Corporation (QDEL) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering QuidelOrtho Corporation (QDEL) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering QuidelOrtho Corporation (QDEL) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering QuidelOrtho Corporation (QDEL) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering QuidelOrtho Corporation (QDEL) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering QuidelOrtho Corporation (QDEL) market action, institutional positioning, and fundamental catalysts.
The street is overcomplicating QuidelOrtho Corporation (QDEL). Institutional whale 13F flow scores 9/20, the strongest pillar, indicating accumulation and options positioning that is more constructive than the fundamentals.. With an RQD score of 21/100 (E) and Forensic Balance Sheet at 6/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $14.31.
Both sides have a point here — QDEL's 6/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
ROIC of -35%, FCF yield of -8.8%, and an Altman Z-Score of 0.2 show the business is destroying capital and sits in a distressed forensic range.. Look at the math on QDEL: paying current EV/EBITDA multiples for -35.0% ROIC and -33.7% operating margins leaves zero margin of safety if Biotechnology: In Vitro & In Vivo Diagnostic Substances demand softens. I'd wait for a retest of $11.66 before getting long.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: